Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Oral and Maxillofacial RadiologyPhysiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT
Section snippets
Materials and Methods
The distribution of healthy salivary and seromucous gland tissues in the head and neck area was retrospectively analyzed in 30 consecutive patients who underwent total body PSMA PET/CT for staging of prostate cancer in March and April 2016. Exclusion criteria were previous salivary gland disease, aberrant tracer uptake suspected of neoplasia, and previous surgery and/or radiotherapy in the head and neck region.
PSMA PET/CT
The 30 male patients had an average age of 68 years (range 54-82 years). The mean administered activity was 173 ± 29 MBq (range 131-273 MBq). The mean time interval between tracer administration and imaging was 66 minutes (interquartile range 58-74 minutes).
PSMA-ligand uptake
All scans clearly depicted anatomic areas of salivary, seromucous, and lacrimal gland concentrations by visualizing high and homogenous uptake of PSMA-ligand (Figure 2). These areas included the major salivary glands and submucosal minor
Discussion
The results of this study provide a comprehensive qualitative and quantitative overview of tracer accumulation on PSMA PET/CT in salivary, seromucous, and lacrimal gland tissues in the head and neck. The presented distribution patterns of the major salivary glands are comparable to those (to a lesser extent) reported in studies on different topics using the same tracer.9, 10 In addition, our study illustrates the ability of PSMA PET/CT to visualize minor gland locations, for example, in the
Conclusions
PSMA PET/CT consistently depicts high tracer uptake in healthy major and minor salivary glands and lacrimal and seromucous glands. Minor salivary and seromucous glands can now be selectively visualized on imaging. Potential clinical applications of PSMA-ligand visualized by PET/CT include quantification of present salivary gland tissues and individualization of head and neck cancer treatment by radiotherapy field adaptation and 177Lu-PSMA radionuclide treatment of salivary gland cancers.
References (35)
The role of saliva in maintaining oral homeostasis
J Am Dent Assoc
(1989)- et al.
Morphological features of the minor salivary glands
Arch Oral Biol
(1999) - et al.
Frequency and distribution pattern of minor salivary gland tumors in a northeastern Chinese population: a retrospective study of 485 patients
J Oral Maxillofac Surg
(2015) - et al.
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
Urol Oncol
(1995) - et al.
The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research
Urol Oncol
(2014) - et al.
Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy
Semin Ultrasound CT MRI
(2010) - et al.
The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions
J Nucl Med
(2015) - et al.
German multicenter study investigating 177 Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients
J Nucl Med
(2017) - et al.
Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes
Radiat Oncol
(2014) - et al.
Imaging of the major salivary glands
Clin Physiol Funct Imaging
(2016)
Imaging the floor of the mouth and the sublingual space
Radiographics
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Eur J Nucl Med Mol Imaging
Evaluation of practical interpretation hurdles in 68 Ga-PSMA PET/CT in 55 patients: physiological tracer distribution and incidental tracer uptake
Clin Nucl Med
Normal distribution pattern and physiological variants of 68 Ga-PSMA-11 PET/CT imaging
Nucl Med Commun
Mucous glands in the developing human rhinopharynx
Laryngoscope
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
Anticancer Res
Cited by (0)
This research is supported by the Dutch Cancer Society (Research Grant: 10606/2016-2). The authors declare that they have no conflict of interest.
- *
Authors contributed equally to the manuscript.